Understanding how CXCR7 affects drug resistance in lung cancer
Investigation of CXCR7 signaling in EGFR TKI resistant NSCLC
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10672451
This study is looking at how a protein called CXCR7 affects non-small cell lung cancer that doesn't respond to certain treatments, with the goal of finding new ways to help patients who are struggling with drug resistance.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10672451 on ClinicalTrials.gov |
What this research studies
This research investigates the role of CXCR7 in non-small cell lung cancer (NSCLC) that has become resistant to EGFR-targeted therapies. The study aims to uncover the mechanisms by which CXCR7 contributes to this resistance, particularly through a process known as epithelial to mesenchymal transition (EMT). By analyzing patient samples and using specific techniques to inhibit CXCR7, the researchers hope to restore sensitivity to EGFR inhibitors in resistant cancer cells. This could lead to new treatment strategies for patients who currently have limited options due to drug resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer who have developed resistance to EGFR tyrosine kinase inhibitors.
Not a fit: Patients with NSCLC who have not been treated with EGFR inhibitors or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with drug-resistant NSCLC.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHIMAMURA, TAKESHI — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: SHIMAMURA, TAKESHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, NSCLC - Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer